Yann Godbert

Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers

Lori J. Wirth, Eric J. Sherman, Bruce Robinson et al. · New England Journal of Medicine · 2020 · 773 citations · Full text

Medicine, Endocrinology, Oncology +16

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

Vivek Subbiah, Mimi I. Hu, Lori J. Wirth et al. · The Lancet Diabetes & Endocrinology · 2021 · 353 citations · Full text

Medicine, Endocrinology, Oncology +9

Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer

Sophie Leboulleux, Claire Bournaud, C. Chougnet et al. · New England Journal of Medicine · 2022 · 227 citations · Full text

Medicine, Oncology, Surgery +17

Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial

Martin Schlumberger, Sophie Leboulleux, Bogdan Catargi et al. · The Lancet Diabetes & Endocrinology · 2018 · 165 citations

Medicine, Oncology, Surgery +11

Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase–Rearranged Anaplastic Thyroid Carcinoma

Yann Godbert, Bénédicte Henriques de Figueiredo, F. Bonichon et al. · Journal of Clinical Oncology · 2014 · 144 citations

Medicine, Oncology, Pharmacology +10